Clinical Trial

Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-center, single-arm clinical study to evaluate the efficacy and safety of iparomlimab and tovorilimab (QL1706) combined with paclitaxel, carboplatin, and bevacizumab as neoadjuvant therapy for advanced ovarian cancer.
Trial Details
NCT Number NCT07663513
Lead Sponsor Fudan University
Conditions Ovarian Cancers
Enrollment 36 participants
Start Date 2026-07
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-23